Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label, single ascending dose, dose-ranging phase I/II study of TX200.

Next Previous
Trial Profile

A multicenter, open-label, single ascending dose, dose-ranging phase I/II study of TX200.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TX-200 (Primary)
  • Indications Transplant rejection
  • Focus Adverse reactions; First in man
  • Acronyms STEADFAST

    • Most Recent Events

    • 19 Nov 2019 According to a Sangamo Therapeutics media release, the company expects to open the first clinical site in 2020.
    • 19 Nov 2019 According to a Sangamo Therapeutics media release, that the United Kingdom's (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy.
    • 07 Aug 2019 According to a Sangamo Therapeutics media release, company is remain on track to file CTA in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top